{
    "data": [
        {
            "id": "4130674",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-20T10:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4130674-jonathan-faison-positions-for-2018-faster-fda-approval-emerging-sector-in-china-bode-well-for"
            }
        },
        {
            "id": "4132762",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-19T12:44:42-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Could Improved FDA Policies Help NKTR-181?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195892",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4132762-nektar-therapeutics-improved-fda-policies-help-nktrminus-181"
            }
        },
        {
            "id": "4130821",
            "type": "article",
            "attributes": {
                "publishOn": "2017-12-09T12:13:12-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Notable BioSci Mover On Dec. 7, 2017 - Nektar Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195547",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4130821-notable-biosci-mover-on-dec-7-2017-nektar-therapeutics"
            }
        },
        {
            "id": "4128357",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-29T08:26:13-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Hold On To Nektar Therapeutics: There Is Much More Ammunition Left In Its Partnered Research Programs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "195205",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4128357-hold-on-to-nektar-therapeutics-is-much-ammunition-left-in-partnered-research-programs"
            }
        },
        {
            "id": "4124012",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-13T01:29:13-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Encouraging Data Revealed At SITC",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194553",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4124012-nektar-therapeutics-encouraging-data-revealed-sitc"
            }
        },
        {
            "id": "4122509",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-08T15:58:33-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics Spotlight: Watch For NKTR-214 Results This Weekend At Society For Immunotherapy Of Cancer Annual Meeting",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102730",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4122509-nektar-therapeutics-spotlight-watch-for-nktrminus-214-results-this-weekend-society-for"
            }
        },
        {
            "id": "4122188",
            "type": "article",
            "attributes": {
                "publishOn": "2017-11-08T09:16:42-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Updates To Thesis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "194407",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4122188-nektar-therapeutics-updates-to-thesis"
            }
        },
        {
            "id": "4109806",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-27T10:12:43-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Nektar's Potential, Axovant Finally Fails, PTCT AdComm Tomorrow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4109806-your-daily-pharma-scoop-nektars-potential-axovant-finally-fails-ptct-adcomm-tomorrow"
            }
        },
        {
            "id": "4109403",
            "type": "article",
            "attributes": {
                "publishOn": "2017-09-26T06:18:16-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics Building A More Exciting Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4109403-nektar-therapeutics-building-exciting-pipeline"
            }
        },
        {
            "id": "4096493",
            "type": "article",
            "attributes": {
                "publishOn": "2017-08-08T16:21:17-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Nektar's Etirinotecan Pegol Get A Second Chance?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4096493-will-nektars-etirinotecan-pegol-get-second-chance"
            }
        },
        {
            "id": "4091331",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-27T13:02:47-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: Further Upside Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "190361",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4091331-nektar-therapeutics-upside-ahead"
            }
        },
        {
            "id": "4090358",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-25T16:10:23-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Makes A Stride Forward In Resolving Autoimmune Diseases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "190255",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4090358-nektar-makes-stride-forward-in-resolving-autoimmune-diseases"
            }
        },
        {
            "id": "4090113",
            "type": "article",
            "attributes": {
                "publishOn": "2017-07-25T07:22:04-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lilly Hopes To Bloom Through Nektar Attraction",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4090113-lilly-hopes-to-bloom-through-nektar-attraction"
            }
        },
        {
            "id": "4081404",
            "type": "article",
            "attributes": {
                "publishOn": "2017-06-14T11:22:17-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: A Sweet Or Sour Investment?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "188645",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4081404-nektar-therapeutics-sweet-sour-investment"
            }
        },
        {
            "id": "4071094",
            "type": "article",
            "attributes": {
                "publishOn": "2017-05-09T12:02:52-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Showtime For Nektar Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58081",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "187285",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4071094-showtime-for-nektar-therapeutics"
            }
        },
        {
            "id": "4060473",
            "type": "article",
            "attributes": {
                "publishOn": "2017-04-05T12:35:45-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Quick Evaluation Of Nektar Therapeutics' PEGylation Platform",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "47291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4060473-quick-evaluation-of-nektar-therapeutics-pegylation-platform"
            }
        },
        {
            "id": "4056899",
            "type": "article",
            "attributes": {
                "publishOn": "2017-03-21T15:19:50-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Reaches The Summit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4056899-nektar-reaches-summit"
            }
        },
        {
            "id": "4040725",
            "type": "article",
            "attributes": {
                "publishOn": "2017-01-30T13:30:23-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Expecting Significant Appreciation For Nektar In 2017",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "183582",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4040725-expecting-significant-appreciation-for-nektar-in-2017"
            }
        },
        {
            "id": "4038257",
            "type": "article",
            "attributes": {
                "publishOn": "2017-01-20T10:10:42-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Nektar Therapeutics: An Undervalued Biopharmaceuticals Company With Plenty In The Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102543",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "183210",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1952",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4038257-nektar-therapeutics-undervalued-biopharmaceuticals-company-plenty-in-pipeline"
            }
        }
    ]
}